41
Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological Chemistry

Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

Embed Size (px)

Citation preview

Page 1: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

Navigating the NIH Funding Process

Barbara Gerratana, Ph.D.National Institute of General Medical Sciences

Division of Pharmacology, Physiology & Biological Chemistry

Page 2: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

2

Outline

Outline

NIH organization

Some resources

The funding cycle

NIGMS funding opportunity

Diversity funding opportunities

Page 3: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

3

NIH Mission & Budget

NIH is the steward of medical and behavioral research for the Nation. Its mission is science in pursuit of fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to extend healthy life and reduce the burdens of illness and disability.

$29.1 BillionFiscal Year 2013

Annual Budget

1.7 Billion less than FY2012

Intramural Research

R&D Contracts

Research Centers

Other ResearchGrants

All Other Training

Mgmt & Support3%

3% 5%

6% Research ProjectGrants (RPG)

53% 10%

11% 10%

NIH organization

Page 4: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

4

27 Institutes & Centers

Office of the Director

National Libraryof Medicine

Center for InformationTechnology

Center for Scientific Review

FogartyInternational

Center

National Instituteof Arthritis andMusculoskeletal

and Skin Diseases

National Instituteof Diabetes andDigestive and

Kidney Diseases

National Instituteof Dental andCraniofacial

Research

National Institute onDeafness and Other

CommunicationDisorders

National EyeInstitute

National Heart,Lung, and Blood

Institute

National Instituteon Alcohol Abuseand Alcoholism

National CancerInstitute

National Instituteof Environmental Health Sciences

National Instituteof Mental Health

National Instituteof NeurologicalDisorders and

Stroke

National Instituteof Allergy and

Infectious Diseases

National Center on Minority Health and Health Disparities

National Instituteon Aging

National Instituteof Child Health

and HumanDevelopment

National HumanGenome Research

Institute

National Instituteof General

Medical Sciences

National Instituteof Nursing Research

National Centerfor Complementary

and AlternativeMedicine

National Centerfor ResearchResources

Clinical Center

National Institute of Biomedical Imaging and Bioengineering

no fundingauthority

National Instituteon Drug Abuse

National Centerfor Advancing

Translational Sciences

NIH organization

Page 5: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

5

NIGMS Mission

The general purpose of the National Institute of General Medical Sciences is the conduct and support of research, training, and as appropriate, health information dissemination, and other programs with respect to general or basic medical sciences and related natural or behavioral sciences which have significance for two or more national research institutes or are outside the general area of responsibility of any other national research institute.

5 Divisions:

Biomedical Technology, Bioinformatics, and Computational Biology

Cell Biology and Biophysics

Training, Workforce Development, and Diversity

Genetics and Developmental Biology

Pharmacology, Physiology, and Biological Chemistry

NIH organization

Page 6: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

6

NIH Institute Funding

Buildings & Facilities

1,0591,039

Drug Abuse

Aging

65118120136260

318318

387392432483504

645662

1,245

1,4351,532

4,2314,779

2,901

1,6932,291

$0 $1,000 $2,000 $3,000 $4,000 $5,000Fogarty International

Comp. Med.

Nursing

Minority Health

Bio Imaging

Library

Dental

Deafness

Alcohol Abuse

Genome

Arthritis

Environmental Health

Eye

Child Health

Mental Health

Neurology

Diabetes, Kidney

General Medical Sciences

Heart, Lung, Blood

Allergy, Infectious

Cancer

$29.1 BillionFiscal Year 2013

Office of the Director

1,394

NCATS 542

(Dollars in millions)

NIH organization

Page 7: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

7

Outline

Outline

NIH organization

Some resources

The funding cycle

NIGMS Funding opportunity

Diversity funding opportunities

Page 8: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

8

NIGMS Feedback Loop

• Get NIGMS news as it happens!

• Regular updates on funding opportunities

• Post your comments

• Ask questions

• Sign up for e-mail updates or RSS feed

http://

www.nigms.nih.gov/News/FeedbackLoop.htm

Application resources

August 5th, 2013

Page 9: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

9

RePORTER projectreporter.nih.gov

Application resources

Page 10: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

10

NIH Grant Writing Resources

Application resources

grants.nih.gov/grants/grant_tips.htmNIH Central Resource Site

http://grants.nih.gov/grants/new_investigators/New Investigators

NIGMS www.nigms.nih.gov/Research/Application/Tips.htm

NCI deainfo.nci.nih.gov/extra/extdocs/gntapp.pdf

NIAID* funding.niaid.nih.gov/researchfunding/grant/pages/aag.aspx

NINDS www.ninds.nih.gov/funding/grantwriting.htm

Page 11: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

11

Grant Writer’s Handbook

Application resources

HHMI “Making the Right Moves” http://www.hhmi.org/resources/labmanagement/

“Writing the NIH Grant Proposal: A Step-by Step Guide” by William Gerin

“Grant Application Writers Handbook” by Liane Reif-Lehrer

“Guide to Effective Grant Writing: How to Write a Successful NIH Grant Application” by Otto O. Yang

“How to Succeed in Academics” by Edward R. B. McCabe and Linda McCabe

“The Grant Application Writer’s Workbook” available at GrantCentral.com

Page 12: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

12

NIGMS Mentoring Workshop for New Bio/Chemistry Faculty Since 2005

Application resources

Mentoring is more than teaching someone to be just like you!

NIGMS

• Help PIs to convey significance/impact of proposed research

• Provide advice on key non-technical career skills

• Stress the value of mentoring and being mentoring

• Introduce junior faculty to NIH procedures and NIH staff

• Promote networking among young scientists and with senior role models

• 30 Junior faculty participants in organic chemistry and chemical biology

• 6-8 Senior faculty mentors plus NIH staff

• 3 Days of discussions, presentations, and networking

• 2013 Mentors Phil Cole (The Johns Hopkins), Jon Ellman (Yale), Barbara Imperiali (MIT), Jeff Johnson (University of North Carolina), Hening Lin (Cornell University), and Lisa McElwee-White (University of Florida).

Next workshop 06/30-07/02/2013!

http://meetings.nigms.nih.gov/?ID=13578

Page 13: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

13

Outline

Outline

NIH organization

Some info on preparing an

application

The funding cycle

NIGMS funding opportunity

Diversity funding opportunities

Page 14: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

14

Funding Opportunity Announcements (FOAs)

http://grants.nih.gov/grants/oer.htm

Parent Announcements or Unsolicited Applications• Investigator initiated applications• Fit of mission of one of the NIH institutes• Mechanism of the grant should be supported by the Institute of programmatic

relevance

Funding cycle

Page 15: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

15

RFA vs PA

Funding cycle

Announcements

Focus Set-aside funds

Special review criteria and panel

Length of announcement

Receipt dates

RFA Narrowly defined YES YES n/a One date

PAR Specific scientific area but broadly defined

Usually not

YES 3 years Usually standard dates

PAS Specific scientific area but broadly defined

YES Depends 3 years Usually standard dates

RFA = request for ApplicationsPA = program announcementPAR = program announcement reviewed in an InstitutePAS = program announcement with set-aside funds

Page 16: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

16

Most Common Grant Mechanisms

Funding cycle

Mechanism To support Length

Budget

Common goals Receipt dates

R01:Research project single Pi or multi-PIshttp://grants.nih.gov/grants/funding/ac_search_results.htm

Discrete and specified research project in area of expertise

Up to 5 years

$250,000 DC/year but it can be higher

New: Feb 5, June 5 and October 5Renewal: March 5, July 5 and Nov. 5

R21:Exploratory/developmental grantshttp://grants.nih.gov/grants/funding/r21.htm

Development of a new research activities

Up to 2 years

$275.000 DC for 2 years

• Exploratory, novel studies • High risk high reward studies

Projects should be distinct from those supported through the traditional R01 mechanism

New: Feb 16, June 16 and October 16Renewal: March 16, July 16 and Nov. 16

R03:Small research grantshttp://grants.nih.gov/grants/funding/r03.htm

Short-term projects with amount

Up to 2 years

$50,000 DC/year

• Pilot or feasibility studies • Secondary analysis of existing data • Small, self-contained research

projects • Development of research

methodology • Development of new research

technology

New: Feb 16, June 16 and October 16Renewal: March 16, July 16 and Nov. 16

R15:Academic research enhancement awards (AREA) http://grants.nih.gov/grants/funding/area.htm

Small research scale projects at educational institutions that have not been major recipients of NIH support.

Up to 3 years

$300,000 DC for 3 years

• Support meritorious research• Expose students to research• Strengthen the research

environment of the institution

New and renewal: Feb 25, June 25 and October 25

DP2 New Innovator awards http://commonfund.nih.gov/newinnovator/

highly innovative research projects by new investigators

Up to 5 years

$300,000 DC/year

• Individual early stage investigators of exceptional creativity proposing research of uncommonly high potential impact

Not announced yet for 2014 usually end of Summer or beginning of Fall

Page 17: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

17

Funding Cycle

Applicant InitiatesResearch Idea

University Submits

Electronically the

Application

Assign to Institute and

Study Section

Peer Review

Leaders in the biological and medical sciences, education,

health care, and public affairs.

AdvisoryCouncil of the Assigned

Institute

Allocation of Funds

Review of Scientific Merit

Second Review

Conducts Research

InstituteProgram

staff

1st NIH Study Section 1946

Funding Decision

Funding Cycle

Page 18: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

18

Cover Letter & Referral

Funding Cycle

Assign to Institute and

Study Section

The cover letter is important to: • Suggest institute assignment• Suggest study section assignment• Identify individuals in conflict• Identify areas of expertise needed to evaluate the application

The cover letter is NOT appropriate to suggest specific reviewers!

• Is it possible to change the IC and/or study section assignment(s)? YES

• When? BEFORE the review of the application (after it is almost impossible)

• How? Contact the assigned SRO and PO and provide in writing a justification for the desired change

• If my application has a secondary Institute assignment, does the 2ary Institute consider automatically my application if the 1ary Institute does not fund it?

NO Only if the Program Officer of the 2ary Institute has interest in your application it may be considered. This is an extremely rare case and usually applications are transferred before review.

Page 19: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

19

Study Section and Institute, which one?

Funding Cycle

Colleagues, Reporter and web sites of ICs are the first source of information. Program director for confirmation.

STUDY SECTION• Standing Study Sections review most investigator-initiated research

applications (R01, R03, R21, R15, and Ks). Standing study sections are those with both permanent members and temporary members, and are organized by CSR. http://public.csr.nih.gov/StudySections/Standing/Pages/default.aspx

• Special Emphasis Panels one-time or recurring Special Emphasis Panels (SEPs) are held to review applications on special topics and members conflict applications. They include only temporary members. P01, SBIR/STRR…. review by SEPs. SEPs can be organized by CSR or by the review office of an institute.

24 INSTITUTES/CENTERS with funding authority• Not all ICs participate in all mechanisms. For example/ NIGMS does not support

investigated initiated R21 and R03.• Not all ICs participate in all RFA , PAR and PAS.

A standing study section reviews applications assigned to a variety of ICs

Page 20: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

20

Funding Opportunity Announcement (FOA)

Funding Cycle

Page 21: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

21

Submission

Funding Cycle

Applicant InitiatesResearch Idea

University Submits

ApplicationElectronic Submission

NIH

Conducts Research

February 5June 5October 5

New Research Grants

(R type)

January 25May 25September 25

All Program Project and

Center Grants

February 12June 12October 12

New Career Development

Awards (K type)

March 5July 5November 5

Research Grant Renewal,

Resubmission, and Revision

Applications

http://grants.nih.gov/grants/funding/submissionschedule.htm

Page 22: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

22

Due Dates for R01

Only ONE resubmission allowed! Do not waste it by rushing!

NIH allows a shorten review cycle for New Investigator R01 Applications:

Submission Review Council Funding

A0 June 5th October January April ?

Normal A1 March 5th June October ??????

Shorten A1 December 10th

February May July?

NOT RECOMMENDED

You have 37 months from the A0 application date to resubmit. Any applications submitted after the 37 month will be considered a new application.

Funding Cycle

Page 23: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

23

Funding Cycle

Applicant InitiatesResearch Idea

University Submits

Electronically the

Application

Assign to Institute and

Study Section

Peer Review

Leaders in the biological and medical sciences, education,

health care, and public affairs.

AdvisoryCouncil of the Assigned

Institute

Allocation of Funds

Review of Scientific Merit

Second Review

Conducts Research

InstituteProgram

staff

1st NIH Study Section 1946

Funding Decision

Funding Cycle

Page 24: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

24

Criteria Selection for Review Panel Memberships

Funding Cycle

Mandatory criteria:• Scientific expertise is the most important criterium and it depends on the science covered

by the pool of applications considered in a specific round of review

• Geographical distribution: 25% of Central, South, East, West

• Gender and minorities representation: at least 10% for each

Limits in # of reviewers from:• No 2 people from the same Department• For each 10 reviewers 2 can be from the same University (up to 3 for 30 reviewers subjected to

higher level approval)

Optional criteria:• age distribution• one Assistant Professor

SEP specific criterium: the making of the panel will reflect the community – SBIR will have industry people; R15 will have reviewers from qualifying institutions….

Page 25: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

25

Early Career Reviewer (ECR) Program

Funding Cycle

ECR program was developed to:• train qualified scientists without prior CSR review experience so that they may become

effective reviewers, • help emerging researchers advance their careers by exposing them to peer review, and • enrich the existing pool of NIH reviewers by including scientists from less research-intensive

institutions as well as those from traditionally research- intensive institutions

Eligibility for the ECR program includes:• Full-time faculty members or researchers in similar roles. • Evidence of an active independent program of research• Recent publications in peer-reviewed research journals • Has not served on a CSR study section in a role other than a mail reviewer• Prior NIH funding is NOT a requirement

How to apply:• First, send your CV and contact the SRO of the study section of interest• Then, follow the official procedure described at

http://public.csr.nih.gov/ReviewerResources/BecomeAReviewer/Pages/Overview-of-ECR-program.aspx

What will you do:• receive training from SRO on review procedures and how to write critiques• you will have a lighter workload (2-4 applications)• Attend panel and participate in discussion and voting

Page 26: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

26

Review Process of a Standing Study Section

Funding Cycle

• SRO assigns your application to 3 primary reviewers

Reviewers submit preliminary criterion scores (from 1 exceptional to 9 poor) with comments for Significance, Investigator(s), Innovation, Approach and Environment

• SRO determines Review Order

• Persons with conflicts of interest excused• Primary reviewers (3) give preliminary scores (1-9)• Discussion of application’s scientific and technical merit• Other panel members join discussion• Primary reviewers give final scores (1-9)• All panel members (except those in conflict) score privately• Assignment of codes for animals and human subjects protection• Budget recommendations.

• Best scoring application first

• New investigators (best-to-worst) are reviewed separately from others

• Everyone else (best-to-worst)

• About 50% applications will be discussed, remainder unscored (ND, not discussed)

Mock study section video: http://public.csr.nih.gov/Pages/default.aspx

Page 27: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

27

Feedback from Review

Funding Cycle

• Priority Score & Percentile eRA Commons• 1-4 days after meeting• Impact/Priority score is average reviewer score (1-9) times ten (10-90)• Percentile: relative ranking of application with last 3 meetings of study

panel• Not all applications get percentiled (e.g. R15, for GM F32s and K99s

are not percentiled)

• Summary Statement eRA Commons• SRO prepares and releases• 10 (New PIs) – 30 (all others) days after meeting for R01s• Summary of discussion written by SRO• Criteria scores from assigned reviewers• Critiques from assigned reviewers • Budget recommendations• Administrative notes• Codes for Animal Vertebrates and Human Subjects

• Assigned Program Officer• Typically present at review meeting• Interpret comments• Advice on resubmission

Final scores of primary reviewers are NOT an average of the criteria scores!

Page 28: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

28

Funding Cycle

Applicant InitiatesResearch Idea

University Submits

Electronically the

Application

Assign to Institute and

Study Section

Peer Review

Leaders in the biological and medical sciences, education,

health care, and public affairs.

AdvisoryCouncil of the Assigned

Institute

Allocation of Funds

Review of Scientific Merit

Second Review

Conducts Research

InstituteProgram

staff

1st NIH Study Section 1946

Funding Decision

Funding Cycle

Page 29: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

29

Second Level of Review: Advisory Council

Funding Cycle

• Provides oversight to insure initial review was fair and in compliance with NIH policy

• Most applications are voted en bloc by Council• Council usually discuss specific applications if there are appeal, program

projects, Merit award,. etc.

Council does not make funding decisions

Page 30: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

30

Funding Cycle

Applicant InitiatesResearch Idea

University Submits

Electronically the

Application

Assign to Institute and

Study Section

Peer Review

Leaders in the biological and medical sciences, education,

health care, and public affairs.

AdvisoryCouncil of the Assigned

Institute

Allocation of Funds

Review of Scientific Merit

Second Review

Conducts Research

InstituteProgram

staff

1st NIH Study Section 1946

Funding Decision

Funding Cycle

Page 31: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

31

Funding Decision by IC Program Staff

Funding Cycle

• Applications are ranked based on Priority Score (Fs, Ks) or Percentile ranking (R01s)

• Paylines are decided based on availability of funds• Paylines vary from different types of grants• Paylines may be more liberal for New (or ESI) investigators

Unofficial but updated and comprehensive source of paylines of all ICs: http://www.einstein.yu.edu/administration/grant-support/nih-paylines.aspx

Institutes with set paylines (NIAID, NCI*..)

Institutes without set paylines: NIGMS example

• Applications are ranked based on Priority Score (Fs, Ks) or Percentile ranking (R01s)

• Top-scoring applications are given the highest priority for funding• A “grey area” of applications is identified based on available funds just after

the top scoring applications. Not all the applications in the grey area will be funded.

• Applications in the “grey area” are ranked for funding consideration based on:

Percentile, Programmatic needs, Other support of applicant, ESI or New investigator, If council has recommendations

Page 32: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

32

When and Who to Contact

Funding Cycle

WHEN WHO

Before and as you prepare your application

Mentors/colleaguesInstitute Program Officer

When you register for eRA Commons eRA Commons Help Desk

Submission Grants.gov Help Desk

Receipt & Referral Scientific Review Offcier (SRO) and Program Officer

Before Review SRO

After and about the review Program Officer

Funding decision Program Officer

Award Program Officer and Grants Management Specialist

Page 33: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

33

Resubmission

Funding Cycle

Only ONE resubmission allowed! Do not waste it by rushing!

NIH allows a shorten review cycle for New Investigator R01 Applications:

Submission Review Council

A0 June 5th October January

Normal A1 March 5th June October

Shorten A1 December 10th

February May

NOT RECOMMENDED

You have 37 months from the A0 application date to resubmit. Any applications submitted after the 37 month will be considered a new application.

Page 34: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

34

Outline

Outline

NIH organization

Some info on preparing an

application

The funding cycle

NIGMS funding opportunity

Diversity funding opportunities

Page 35: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

35

NIGMS Collaborative Supplementhttp://www.nigms.nih.gov/Research/FeaturedPrograms/Collaborative/SCS.htm, http://grants.nih.gov/grants/guide/notice-files/NOT-GM-11-117.html

NIGMS Funding opportunity

Main eligibility criteria:• New collaborations i.e. no publications or collaboration in the last 3

years and  no mention in the parent grant• Collaborative research should be within the scope of the grant• All members should have financial support (not necessarily NIH

support other is fine)• Collaborators may be foreign• PIs funded by an NIGMS R01, R37 or SC1 grant with at least 18

months of active funding on the parent grant at the time of the receipt date deadline are eligible to apply

Main facts:• Deadlines January 15th and May15th • $90,000 direct cost/year up to 3 years for the PI and one

collaborating group. An additional $45,000  direct cost/year up to 3 years for a second collaborating group

• No $ for PI salary• Proposed work could not have been foreseen/planned at the time

of the parent grant application• Strong rational for collaboration• Intellectual involvement of all the PIs• Reviewed internally by NIGMS committee

Page 37: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

37

Outline

Outline

NIH organization

Some info on preparing an

application

The funding cycle

NIGMS funding opportunity

Diversity funding opportunities

Page 38: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

38

NIGMS Diversity Supplement

http://www.nigms.nih.gov/Research/Mechanisms/PromoteDiversity.htm, http://www.nigms.nih.gov/Research/Mechanisms/DiversityPhilosophy.htm,http://grants.nih.gov/grants/guide/pa-files/PA-08-190.html

Diversity funding opportunity

To support an US citizen on a grant at the high school, undergraduate, post-baccalaureate, graduate student or postdoctoral fellow levels.

Main eligibility criteria and philosophy:• There should be at least 2 years or more of support remaining at the time of the

supplement on the parent grant• Individuals (proposed for support) should not have been funded by the parent

grant prior to the application • To support individuals in early stages of their training (generally first 1 or 2 years)

with the expectation that individuals will transition to traditional means of support• Up to $75,000 direct cost/year• No deadlines

For additional information on diversity supplements, see the NIH Guide for Grants and Contracts, July 2, 2008 (PA-08-190), or contact Dr. Marion Zatz at [email protected], 301-594-3833.

Page 39: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

39

Score Program http://www.nigms.nih.gov/Training/MBRS/SCOREDescription.htm

Diversity funding opportunity

Three Score programs fund investigator initiated research applications fitting an IC mission:• SC1 (Research Advancement Award) research support for research project in

advanced stage planning to transition to non-Score support• SC2 (Pilot Project Award) research support for early stages of development of a

research plan. It allows to test new idea or gather preliminary data in a new line of research.

• SC3 (Research Continuance Award) research support for research project in an intermediate stage of development

Institution eligibility• 4-years colleges, MS or Ph.D. granting Universities serving underrepresented

minority students • Institutions receiving less than 6 million dollars from NIH R01 support in the last

two fiscal years

PI eligibility• Full time regular faculty appointment• Faculty with a track record of external support (other than MBRS) and publications

are ineligible• Faculty currently receiving other individual or institutional developmental research

support are ineligible

Page 40: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

40

Score Program http://www.nigms.nih.gov/Training/MBRS/SCOREDescription.htm

Diversity funding opportunity

SC1 Research Advancement Award

SC2 Pilot Project Award

SC3 Research Continuance

Award

Programmatic Goal

Foster the transition to major non-SCORE support

Allows beginning PIs to generate preliminary data to establish a new line of

research

Allows PIs conduct projects of limited scope

and publish

Max Direct Costs

(Modular Budgets)

Up to $250K/yr Up to $100K/yrNot to exceed $300K for

entire project period

Up to $75KNot to exceed $300K for

entire project period

Duration New PIs, who have not had SCORE support- 5 years

Previous SCORE PIs- 4 yearsRenewable once

3 yearsNot renewable

4 yearsRenewable

Common Requirement

PIs developmental objectives and plan to achieve them must be providedNo MPI grant

Other Requirement

s

No other research support PIs must have a mentor and a mentoring plan

No other research support

Other external research support of less than

$75K is allowed

NIGMS contact: Dr. Hinda Zlotnik, Tel. 301-594-3900 , E-mail: [email protected]

Page 41: Navigating the NIH Funding Process Barbara Gerratana, Ph.D. National Institute of General Medical Sciences Division of Pharmacology, Physiology & Biological

NIGMS: Investing in Discovery

Barbara [email protected]

301-594-3827